NASDAQ$SMTI

Sanara MedTech Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Sanara MedTech reported record net revenue for the twelfth consecutive quarter, driven by increased sales of soft tissue repair products, market penetration, and geographic expansion.

Sanara MedTech reported a 35% increase in net revenue to $21.7 million for Q3 2024, marking the twelfth consecutive record net revenue quarter. However, the company experienced a net loss of $2.9 million, primarily due to increased SG&A costs related to the Tissue Health Plus (THP) platform buildout, higher interest expense, and an increase in expense due to change in fair value of earnout liabilities.

  • Net revenue increased by 35% year-over-year to $21.7 million, marking the twelfth consecutive record revenue quarter.
  • The number of facilities selling Sanara's products increased to over 900 in Q3 2024, compared to over 600 in Q3 2023.
  • Net loss was $2.9 million, compared to a net loss of $1.1 million in the same quarter last year, primarily driven by increased SG&A costs for the THP platform.
  • Adjusted EBITDA was $0.8 million, compared to $0.3 million for the quarter ended September 30, 2023.

Headline financials

Total Revenue

$21.7M

Previous: $16M+35.2%
EPS

-$0.34

Previous: -$0.13-161.5%
Adjusted EBITDA

$2.56M

No prior period
Gross margin

91.0%

No prior period
Capital Expenditures

-$134K

Previous: -$211K+36.6%
Free Cash Flow

-$2.99M

Previous: -$1.27M-135.3%
Net Income

-$2.86M

Previous: -$1.06M-169.5%
Operating Income

-$1.92M

Previous: -$907K-112.2%
Gross Profit

$19.7M

Previous: $14.3M+37.9%
Cash & Equivalents

$16.3M

Previous: $6.24M+161.0%
Total Assets

$88.5M

Previous: $75.5M+17.3%
R&D Expense

$1.36M

Previous: $986K+37.8%
Stock-Based Comp

$1.03M

Previous: $858K+19.6%

Revenue & EPS history

Sanara MedTech · Revenue · Quarterly

$21.7M

Q3 2024+35.2%vs Q3 2023
Beat estimate in 10 of 15 quarters(67%)
ActualEstimate

Revenue by segment

Sanara MedTech · $31.6M total across 2 segments · Q2 2023

  • Soft tissue repair
    $15.8M
  • Bone fusion products
    $15.8M

Forward guidance

The company remains focused on continuing to execute its growth strategy and delivering exceptional value to both its customers and shareholders.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

+0.2%

Avg return

Earnings day

-2.3%

Avg return

5 days after

+1.0%

Avg return

30 days after

34%

22 / 64 earnings

Positive

+28.6%

Q4 2014

Best reaction

-25.0%

Q3 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+13.0%+17.3%
Q4 2025-0.3%-7.5%+4.3%
Q3 2025-23.4%-24.9%-7.6%
Q1 2025-9.0%-11.2%-17.9%
Q4 2024-12.6%-15.4%-10.4%
Q3 2024+6.3%-1.0%+2.5%
Q2 2024+14.9%+16.3%+20.2%
Q1 2024-5.0%-2.9%-0.5%
Q4 2023-1.8%-1.1%-13.1%
Q3 2023+18.8%+15.3%+37.5%
Q2 2023-12.5%-13.6%-22.6%
Q1 2023-5.0%-9.2%-5.9%
Q4 2022-0.1%-4.1%+17.9%
Q3 2022+4.1%+7.2%+3.2%
Q2 2022+1.2%-1.7%+13.4%
Q1 2022+5.0%+2.3%-12.2%
Q4 2021+2.5%+10.7%-10.9%
Q3 2021-1.6%-2.2%-15.8%
Q2 2021-8.3%-12.4%-14.5%
Q1 2021+5.2%+14.9%+28.7%
Q4 2020+14.5%+6.8%-4.5%
Q3 2020-4.5%-4.3%+15.7%
Q2 2020+9.8%+13.7%+37.2%
Q1 2020-20.7%-18.2%+28.8%
Q4 2019-4.3%+7.3%+30.9%
Q3 2019-3.9%-5.7%+5.1%
Q2 2019-11.5%-20.1%-17.2%
Q1 2019+0.0%-16.7%-16.7%
Q4 2018+0.0%-16.7%-16.7%
Q3 2018+0.0%+0.0%+0.0%
Q2 2018-10.0%-10.0%-30.0%
Q1 2018+20.0%+0.0%+20.0%
Q4 2017+20.0%+0.0%+20.0%
Q3 2017+0.0%+0.0%-14.3%
Q2 2017+0.0%+16.7%+16.7%
Q1 2017+0.0%+0.0%-22.2%
Q4 2016+0.0%+0.0%-10.0%
Q3 2016-20.0%-20.0%+0.0%
Q2 2016+20.0%+0.0%+0.0%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015+0.0%
Q2 2015+0.0%
Q1 2015+11.1%
Q4 2014+28.6%
Q3 2014+0.0%
Q2 2014+0.0%
Q1 2014+0.0%
Q4 2013+0.0%
Q3 2013+14.3%
Q2 2013+0.0%
Q1 2013+16.7%
Q4 2012-12.5%
Q3 2012-16.7%
Q2 2012+6.7%
Q1 2012+0.0%
Q4 2011-4.3%
Q3 2011+0.0%
Q2 2011-10.3%
Q1 2011-11.1%
Q4 2010+3.1%
Q3 2010-25.0%
Q2 2010+2.9%
Q1 2010+5.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro